Until recently, most clinicians and
|
|
- Samson Fox
- 5 years ago
- Views:
Transcription
1 NEW INSIGHTS INTO THE PATHOLOGY OF CORONARY ARTERY DISEASE * Keith C. Ferdinand, MD, FACC ABSTRACT Atherosclerosis leading to myocardial infarction (MI) is no longer considered a problem of simple mechanical obstruction. The atheroma is a complex structure created by and perpetuating an inflammatory response, which creates a prothrombotic state. It is the thrombus from a ruptured plaque that causes occlusion and ultimately MI, not simply growth of the fatty plaque. As we understand the key components of this complex atheroma, we appreciate emerging risk factors that can provide additional information to the major risk factors identified by the National Cholesterol Education Program, particularly on an individual level. This article reviews the pathophysiology of a developing atherosclerotic plaque and outlines the emerging risk factors (lipid and nonlipid) under investigation. In particular, small, dense low-density lipoprotein and C-reactive protein are reviewed, and recommendations for their incorporation into clinical practice are discussed. Although recommended therapies and their targets are not yet changed, *Based on a presentation given by Dr Ferdinand at a symposium held in conjunction with the American Academy of Physician Assistants 31st Annual Physician Assistant Conference. Clinical Cardiologist and Medical Director, Heartbeats Life Center, and Professor, Clinical Pharmacology, Xavier University College of Pharmacy, New Orleans, Louisiana. Address correspondence to: Keith C. Ferdinand, MD, FACC, Director, Heartbeats Life Center, 1201 Poland Ave, New Orleans, LA kcferdmd@aol.com. testing for certain emerging cardiovascular risk factors can help to identify at-risk individuals who may otherwise be overlooked by populationbased guidelines. (Adv Stud Med. 2003;3(9A):S857-S863) Until recently, most clinicians and researchers considered a myocardial infarction (MI) to be the result of artery blockage by an atherosclerotic plaque. This concept has evolved, however, from a concept of simple mechanical obstruction to a more in-depth understanding of the complex inflammatory processes that lead to MI. Most MIs are not associated with tight stenoses from atherosclerotic plaques. Although these lesions may cause exertional angina (chest pain with exertion), most MIs are the result of a moderate lesion with a superimposed thrombus, typically from a ruptured plaque. To understand this, it is useful to review the pathophysiology of a developing atherosclerotic plaque. UNDERSTANDING THE ATHEROSCLEROTIC PROCESS Atherosclerosis typically begins as a fatty streak along the inside of the artery in which excess cholesterol, in the form of low-density lipoprotein (LDL) cholesterol, accumulates. LDL cholesterol usually functions as a delivery mechanism of cholesterol from the liver and intestines to various tissues, which use Advanced Studies in Medicine S857
2 cholesterol in a wide range of metabolic processes, including membrane repair and steroid production. Excess dietary cholesterol results in excess LDL ( bad ) cholesterol, which then accumulates inside the arterial wall when the tissues are not in need of cholesterol. LDL cholesterol becomes enmeshed in the matrix of the intima (the arterial layer closest to the inside of the artery, containing endothelium, the extracellular matrix, and smooth muscle cells, which produce the connective tissue of the matrix). LDL cholesterol attached to artery walls undergoes oxidation and glycation. This modified form of LDL emits proinflammatory signals to the immune system. 1 The first response by the immune system is the attachment of monocytes (circulating white blood cells) to adhesion molecules on arterial endothelial cells. Once attached, monocytes can squeeze through the epithelial cells to the inner intima. Once inside, they form macrophages and begin to ingest the modified (oxidized) LDL. They ultimately consume so much LDL cholesterol that the fatty droplets inside the macrophage look like foam under a microscope. Thus, these cells are referred to as foam cells. During this time, T-cells are also recruited to the site. 1 As in other inflammatory responses, a braking mechanism for the inflammatory response is in place to begin healing the wound. In this case, the smooth muscle cells from below the intima resurface to the plaque and secrete matrix components to build a fibrous cap over the plaque. As this occurs, some foam cells die, releasing their fatty contents (including the oxidized LDL) into the center of the plaque. This region is often referred to as the lipid or necrotic core. Inside the lipid core, macrophages and T-cells release cytokines to recruit more monocytes to the complex atheroma. Thus, a vicious cycle continues: monocytes are continuously recruited to the complex atheroma, ingesting further oxidized LDL and forming foam cells, which rupture and release more oxidized LDL, as well as cytokines to recruit monocytes. 2,3 High-density lipoprotein (HDL) cholesterol is an important component of the braking mechanism because it inhibits LDL oxidation and effluxes the cholesterol back out into the bloodstream from the lipid core. 4 Of particular import, however, is that the plaque and its cap do not initially narrow the lumen of the artery. Rather, the plaque is formed within the structure of the arterial wall. This process, known as remodeling, allows near-normal blood flow to be maintained. Thus, angiography does not always reveal stenosis when cholesterol levels are abnormally high. 5 MI occurs when a plaque ruptures, causing a blood clot to form over the break. The blood clot is spurred on by procoagulation proteins within the lipid core of the plaque. Many clots may be cleared naturally; some may cause an even larger atheroma as the ruptured plaque is repaired, but those that do block blood flow cause an MI or unstable angina. 5 Clearly, atherosclerosis is insidious. Results from the Bogalusa Heart study, a long-term epidemiologic investigation of the early natural history of atherosclerosis, confirm this. The study began in 1973 to 1974, with height, weight, and lipid-level data from children ranging in age from birth through 14 years in a biracial (black and white) population in Bogalusa, Louisiana. From the wealth of information gleaned from this large dataset, a stark trend emerges showing that atherosclerosis begins early in life even before age 20 years in most patients. 6,7 In middle age, especially in those with type 2 diabetes (another emerging epidemic), the risk for platelet aggregation, vasoconstriction, and blood clotting increases dramatically. In these cases, 40% to 60% stenosis is common, and patients who have moderate coronary artery disease are at a greatly increased risk for an MI. Given what is now known about the perils of atherosclerosis, it behooves clinicians to identify risk factors for atherosclerosis and ways to reduce them. The major risk factors are well known: high LDL cholesterol levels, low HDL cholesterol levels, hypertension, increasing age, male sex, diabetes, and cigarette smoking. The Third Adult Treatment Panel of the National Cholesterol Education Program (NCEP ATP III) has identified diabetes as a coronary heart disease (CHD) risk equivalent 8 ; ie, having type 2 diabetes puts one at as much risk for a future CHD event as having had a previous MI. Young women are at less risk for CHD, perhaps because of estrogen. However, premenopausal women with type 2 diabetes lose this cardiovascular benefit. A prominent focus of public health initiatives is to reduce these major risk factors, in particular, reducing cholesterol levels. However, total cholesterol does not provide a complete picture of CHD risk. Data from the Framingham Heart Study (with 26-year followup) show that fully half of CHD occurs in those with total cholesterol levels below the average level (220 mg/dl); 35% of CHD occurs in those with total cho- S858 Vol. 3 (9A) October 2003
3 lesterol levels below 200 mg/dl. 9,10 As a result, the NCEP ATP III acknowledges that CHD risk is influenced by other factors not included in the major independent risk factors outlined above. Although the Framingham score provides estimates of CHD risk in populations, emerging risk factors under investigation could enhance the predictive power of CHD risk in individuals. 8 EMERGING CHD RISK FACTORS The emerging CHD risk factors can be divided into 2 groups: lipid and nonlipid (Table). Lipid risk factors define cholesterol levels in further detail from the standard lipid profile (ie, LDL cholesterol, HDL cholesterol, triglycerides, and total cholesterol). For example, the size of the LDL particle affects risk the smaller the LDL particle, the greater the risk. Similarly, larger HDL particles, particularly HDL cholesterol, 2 are somewhat more protective. However, NCEP ATP III at this time does not recommend regular testing of these subfractions; the tests for measuring them are not readily available, and their use as independent risk factors is not established. They can be used, however, to support the implementation of therapeutic lifestyle changes. 8 Nonlipid risk factors include markers of inflammation (eg, C-reactive protein [CRP]), thrombogenic/ hemostatic factors, impaired fasting glucose (often a precursor to frank diabetes), and homocysteine. This article will focus on CRP. LIPID FACTORS: SMALL DENSE LDL LDL cholesterol can be further fractionated based on its density. Researchers are examining the possible differences in heart disease risk based on density of LDL, theorizing that smaller, denser LDL particles are more easily able to penetrate the arterial endothelium and therefore are more atherogenic. As a result, small dense LDL particles may better predict cardiovascular events. Several small studies have shown that patients with small dense LDL are at greater risk for ischemic heart disease. A study of 2034 men in the Quebec Cardiovascular Study showed that small dense LDL particles (<255 Å width) are strongly associated with the risk of ischemic heart disease (Figure 1), regardless of LDL cholesterol levels above 146 mg/dl. 11 Clearly, more work needs to be done to clarify these results and provide insight into the relationship of lipoprotein density and CHD. LIPID FACTORS: TRIGLYCERIDES AND NON-HDL CHOLESTEROL It is difficult to determine whether triglyceride level is an independent risk factor. Triglyceride levels appear to be related to CHD risk, but a better way of assessing their impact is via non-hdl cholesterol. Non- HDL cholesterol is measured by subtracting HDL cholesterol values from total cholesterol levels (Figure 2). If serum triglyceride levels are moderately high Table. Emerging Risk Factors LIPID Lipoprotein(a) Small dense LDL HDL Triglycerides and lipoprotein remnants NONLIPID Inflammatory markers (CRP) Thrombogenic/hemostatic factors Impaired fasting glucose Homocysteine LDL = low-density lipoprotein; HDL = high-density lipoprotein; CRP = C-reactive protein. Figure 1. Small Dense LDL and Cardiovascular Risk: Results from the Quebec Cardiovascular Study LDL = low-density lipoprotein. Reproduced with permission from St-Pierre et al. Circulation. 2001; 104: Advanced Studies in Medicine S859
4 ( 200 mg/dl), calculating non-hdl cholesterol offers some assessment of risk. Non-HDL cholesterol includes all atherogenic lipoprotein particles, including LDL, lipoprotein(a), intermediate-density lipoprotein cholesterol, and very-low-density lipoprotein cholesterol, which is a measure of atherogenic remnant lipoproteins. 8 Results from the Lipid Research Clinics Program Follow-up Study show that levels of HDL and non-hdl cholesterol at baseline were significant and strong predictors of death from cardiovascular disease in both sexes (mean follow-up, 19 years; N = 2462). 12 The NCEP ATP III guidelines recommend cutoff points for triglyceride levels as follows: normal, below 150 mg/dl; borderline high, 150 to 199 mg/dl; high, 200 to 499 mg/dl; very high, 500 mg/dl or above. Very high levels confer risk of acute pancreatitis, and drug treatment is therefore recommended. Lifestyle modification, weight loss, and decreased alcohol consumption may have an impact in patients with marginally elevated triglycerides. CRP is linked to atherothrombosis through several mechanisms. Cytokines released from the atheroma include interleukin-6, tumor necrosis factor-alpha, and interleukin- 1B. They are not measured directly, so hscrp is considered a surrogate marker for those cytokines in an atheroma. CRP is easier to measure because it is more stable (ie, can be kept in samples for long periods of time), and a cost-effective assay is available in most clinical laboratories. Measuring hscrp can help to Figure 2. Non-HDL Cholesterol Non-HDL cholesterol = total cholesterol HDL cholesterol = LDL cholesterol + VLDL cholesterol Total cholesterol = LDL cholesterol + HDL cholesterol + (Triglycerides/5)* NONLIPID RISK FACTORS: CRP CRP is gaining great interest, in part because it is more clearly associated with acute coronary artery disease than triglycerides, HDL, or homocysteine. CRP is an acute-phase protein produced by the liver in response to cytokines released in the complex atheroma. A form of CRP assessment, called high-sensitivity CRP (hscrp), provides an accurate measure of CRP when it is present in very low levels. In large population studies, hscrp has been associated with an increase in coronary events. However, some factors may confound the results of hscrp testing. Cigarette smokers may have elevated hscrp levels without complex atheromas; hscrp may also be an innocent bystander during a nonatheroma-related inflammatory response, thus showing misleadingly high levels. Prior infection with chlamydia, Helicobacter pylorus, or cytomegalovirus will confound hscrp results. Assessing risk by simply obtaining blood levels of hscrp can therefore be difficult. *Valid only for persons with triglyceride levels below 400 mg/dl. HDL = high-density lipoprotein; LDL = low-density lipoprotein; VLDL = very-low-density lipoprotein. Data from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 8 Figure 3. Risk Markers for Future Cardiovascular Events: Results from the Women s Health Study hscrp = high-sensitivity C-reactive protein; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein. Data from Ridker et al. 13 S860 Vol. 3 (9A) October 2003
5 assess risk in people with subclinical atherosclerosis who require other means of measuring plaque buildup (eg, electron beam computed tomography, anklebrachial index), as well as help to identify those prone to an acute coronary event. Patients with insulin resistance, obesity, or the metabolic syndrome may underestimate their risk based on major risk factors alone; hscrp may provide greater insight into their risk. Finally, hscrp can also assist in determining plaque vulnerability (ie, the likelihood that an atherosclerotic plaque will rupture). The Women s Health Study provides clear evidence that hscrp may provide additional predictive value for future cardiovascular events. 13 In this study, premenopausal women were followed up for a mean of 3 years to assess risk of cardiovascular events, after measuring baseline levels of markers of inflammation. Cardiovascular events were defined as death from CHD, nonfatal MI or stroke, or the need for coronary revascularization procedures. Of all the markers analyzed, hscrp showed a high predictive value in determining risk of future events (Figure 3), followed by the ratio of total cholesterol to HDL cholesterol. A higher ratio indicates that the level of HDL is low compared with the level of total cholesterol. The goal is therefore to lower the ratio. The relationship among hscrp, total cholesterol, and risk of coronary events is shown in Figure 4. Based on these results, we infer that unstable plaques have an increase in leukocytes (monocytes and macrophages) and T-cells. They rupture, releasing cytokines, which are indirectly measured by hscrp. The corollary suggests that lipid lowering may reduce plaque formation, stabilize existing plaques, and reduce the numbers of macrophages, cytokine levels, and perhaps, the probability of an acute coronary event. Reducing the degree of stenosis is not the only or most important therapeutic objective; just stabilizing the plaque to prevent rupture is. Aspirin is used to prevent blood clots and as an anti-inflammatory drug. In the Physicians Health Study, the use of aspirin significantly decreased the risk of MI in more then 1000 healthy men, with the greatest benefit in those with the highest levels of CRP. CRP level also strongly correlated with risk of MI or stroke (Figure 5). 14 More recently, the Women s Health Study compared the predictive value of hscrp and LDL cholesterol in healthy women. 15 Although hscrp and LDL cholesterol were minimally correlated, each Figure 4. hscrp, Lipids, and Risk of Coronary Events: Results from the Women s Health Study hscrp = high-sensitivity C-reactive protein. Adapted with permission from Ridker et al. N Engl J Med. 2000;342(12): Copyright 2000 Massachusetts Medical Society. All rights reserved. Figure 5. CRP,Aspirin, and Risk of MI: Results from the Physicians Health Study CRP = C-reactive protein; MI = myocardial infarction. Adapted with permission from Ridker et al. N Engl J Med. 1997; 336(14): Copyright 1997 Massachusetts Medical Society. All rights reserved. Advanced Studies in Medicine S861
6 was a strong predictor of future cardiovascular events based on mean 8-year follow-up. These results were also seen in subgroup analyses of users and nonusers of hormone therapy (Figure 6). These results suggest that hscrp and LDL cholesterol levels identified 2 different groups of women who are at risk for cardiovascular events, and that hscrp provides prognostic information that is additional to that found in the Framingham risk score. If hscrp levels appear to predict cardiovascular event risk and provide additive prognostic value, what effect do statins have on hscrp, given their profound beneficial effects on LDL cholesterol levels? A review of the major statin trials shows that statins also have a beneficial effect on hscrp, with decreases of 15% to 20% from baseline (Figure 7). 16 This suggests that statins may also attenuate the inflammatory process in the complex atheroma, although this remains to be proven. Given the strong evidence linking hscrp to the prediction of future cardiovascular events, who should be screened? Earlier this year, the American Heart Association (AHA) released guidelines on the role of hscrp for screening patients at risk for cardiovascular disease. 17 According to the AHA, there is no need to screen the entire adult population for hscrp levels as a public health measure; however, hscrp can be an independent marker of risk and may be useful as a discretionary tool for evaluating individuals with moderate risk. There is not yet enough evidence to support using hscrp to track the efficacy of treatment, despite the effect of statins on hscrp levels. However, the AHA does identify cutoff points for hscrp blood levels to determine the level of risk: low risk, below 1.0 mg/l; average risk, 1.0 to 3.0 mg/l; and high risk, above 3.0 mg/l. Given the effect of statins on hscrp and the unclear relationship between LDL cholesterol and hscrp levels, will statin therapy prevent cardiovascular events in patients with relatively low LDL levels but elevated hscrp? This is currently under investigation in the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study. This randomized placebo-controlled trial is designed to determine whether rosuvastatin (20 mg daily) can decrease coronary events in patients with LDL cholesterol levels below Figure 6. Cardiovascular Event-Free Survival Using Combined hscrp and LDL Cholesterol Measurements hscrp = high-sensitivity C-reactive protein; LDL = low-density lipoprotein. Adapted with permission from Ridker et al. N Engl J Med. 2002;347(20): Copyright 2002 Massachusetts Medical Society. All rights reserved. Figure 7. Effects of Statin Therapy on hscrp hscrp = high-sensitivity C-reactive protein; CARE = Cholesterol and Recurrent Events Trial; PRINCE = Pravastatin Inflammation CRP Evaluation; AFCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study; 4S = Scandinavian Simvastatin Survival Study. Data from Ridker. 16 S862 Vol. 3 (9A) October 2003
7 130 mg/dl and hscrp levels above 2 mg/l. Men older than 55 years and women older than 65 years with no history of coronary disease are being studied. Because this is an event-driven trial, the length will be determined by differences in outcomes; however, follow-up is estimated at 3.5 years. Coronary events are defined as death due to cardiovascular disease, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization. The results may suggest whether we should be more aggressive in treating cardiovascular disease risk and whether hscrp can be used to identify candidates for aggressive LDL reduction. CONCLUSION Atherosclerosis leading to MI is no longer considered a problem of simple mechanical obstruction. The atheroma is a complex structure created by and perpetuating an inflammatory response, which creates a prothrombotic state. It is the thrombus from a ruptured plaque that causes occlusion and, ultimately, MI, rather than just growth of the fatty plaque. As we understand the key components of this complex atheroma, we appreciate emerging risk factors that can provide information that is additional to that provided by the major risk factors identified by the NCEP ATP III, particularly on an individual level. Although recommended therapies and their targets are not yet changed, testing for certain emerging cardiovascular disease risk factors may help to identify at-risk individuals who may otherwise be overlooked by population-based guidelines. REFERENCES 1. Libby P. The vascular biology of atherosclerosis. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, Pa: WB Saunders; 2001: Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320(14): Nathan CF. Secretory products of macrophages. J Clin Invest. 1987;79(2): Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294(pt 3): Libby P. The pathogenesis of atherosclerosis. In: Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison s Principle of Internal Medicine. 15th ed. New York: McGraw Hill Companies; 2001: Urbina EM, Srinivasan SR, Tang R, Bond MG, Kieltyka L, Berenson GS. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). Am J Cardiol. 2002;90(9): Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90(10C):3L-7L. 8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: Castelli WP. Lipids, risk factors, and ischaemic heart disease. Atherosclerosis. 1996;124(suppl):S1-S Castelli WP. Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can J Cardiol. 1988;4:5A. 11. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001;104(19): Cui Y, Blumenthal RS, Flaws JA, et al. Non high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11): Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12): Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14): Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20): Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J. 2001;22(23): Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107: Advanced Studies in Medicine S863
Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationOf the 1.5 million heart attacks
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke Paul M Ridker, MD, MPH Of the 1.5 million heart attacks and 600 000 strokes
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationInspired Functional Ingredients to Innovate and Differentiate Your Brand. Products by Ecovatec Solutions Inc.
Inspired Functional Ingredients to Innovate and Differentiate Your Brand Products by Ecovatec Solutions Inc. High Density Lipopeptides (HDL p ) High Density Lipopeptides (HDL p ) High density lipoproteins
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationMedscape: What do we currently know about the role of CRP as a prognostic marker for primary prevention?
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/500108 Expert Interview C-Reactive Protein -- Inflammatory Marker
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationHealth and Disease of the Cardiovascular system
1 Health and Disease of the Cardiovascular system DR CHRIS MOORE Instructions 2 USE THE ARROWS TO NAVIGATE, OR TAP OUTLINE AT THE TOP TO BRING DOWN A SLIDE MENU Click these where you see them to zoom or
More informationAtherothrombosis And Coronary Artery Disease
Atherothrombosis And Coronary Artery Disease 1 / 6 2 / 6 3 / 6 Atherothrombosis And Coronary Artery Disease Risk factors for coronary artery disease (CAD) were not formally established until the initial
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment
Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment Mandeep Sidhu, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Albany Medical College
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationPRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE
ATHEROSCLEROSIS PRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE Preventing atherosclerosis before it leads to death and disability should now be possible using lifestyle modification and drugs where
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationBerries and Cardiovascular Health
Berries and Cardiovascular Health Britt Burton-Freeman, PhD Institute for Food Safety and Health Illinois Institute of Technology bburton@iit.edu Berry Health Benefits Symposium Westlake Village CA, 2011
More informationDyslipidemia and the Use of Statins. Troy L Randle, DO, FACC, FACOI
Dyslipidemia and the Use of Statins Troy L Randle, DO, FACC, FACOI Objective: Identify CV risk. Determine what dyslipidemia (dyslipoproteinemia) is Decrease CV risk and optimize lipid levels for your
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationROUNDTABLE DISCUSSION: IMPLICATIONS OF ADULT TREATMENT PANEL (ATP) III GUIDELINES AND EMERGENT RESEARCH FOR CLINICAL PRACTICE
ROUNDTABLE DISCUSSION: IMPLICATIONS OF ADULT TREATMENT PANEL (ATP) III GUIDELINES AND EMERGENT RESEARCH FOR CLINICAL PRACTICE The following are excerpts from a roundtable discussion with faculty co-chairs
More informationCHOLESTEROL CONTENT CREATED BY. Learn more at
CHOLESTEROL CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents what is cholesterol? 4 Whether this is your first visit or a follow-up, asking your doctor these
More informationPathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD
Pathophysiology of Cardiovascular System Dr. Hemn Hassan Othman, PhD hemn.othman@univsul.edu.iq What is the circulatory system? The circulatory system carries blood and dissolved substances to and from
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationATHEROSCLEROSIS زيد ثامر جابر. Zaid. Th. Jaber
ATHEROSCLEROSIS زيد ثامر جابر Zaid. Th. Jaber Objectives 1- Review the normal histological features of blood vessels walls. 2-define the atherosclerosis. 3- display the risk factors of atherosclerosis.
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationCholesterol, Heart Attack and Stroke. Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital
Cholesterol, Heart Attack and Stroke Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital Outline Why are we interested in cholesterol What is a heart attack and how does it
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationThe Gender Divide Women, Men and Heart Disease February 2017
The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For
More informationMechanisms of Vascular Dysfunction in Diabetes Mellitus Lynette Pittman, RN, Nurse Clinician, Heart Health Services, Calgary Health Region
Mechanisms of Vascular Dysfunction in Diabetes Mellitus Lynette Pittman, RN, Nurse Clinician, Heart Health Services, Calgary Health Region By 2020 cardiovascular disease (CVD) will dominate all other causes
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationInflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
More informationAssessing Cardiovascular Disease Risk with HS-C-reactive. California Technology Assessment Forum
TITLE: Assessing Cardiovascular Disease Risk with HS-C-reactive Protein AUTHOR: Judith Walsh, M.D., MPH Professor of Medicine Division of General Internal Medicine Department of Medicine University of
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More informationCalcium is a chemical element that is essential for living organisms.
1 of 8 9/28/2015 9:04 AM Home About me Health and Nutrition Diet General Health Heart Disease August 19, 2014 By Axel F. Sigurdsson MD 259 Comments Like Share 82 Calcium is a chemical element that is essential
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationUSING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK
USING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK JAMES M FALKO MD PROFESSOR OF MEDICINE UNIVERSITY OF COLORADO Adapted from: Rader D. N Engl J Med. 2000 hs-crp (mg/l) 6 5 4 3 2 1 *p
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationCoronary Artery Calcium Score
Coronary Artery Calcium Score August 19, 2014 by Axel F. Sigurdsson MD 174 Comments essential for living organisms. Calcium is a chemical element that is Most of the calcium within the human body is found
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationVulnerable Plaque Pathophysiology, Detection, and Intervention. VP: A Local Problem or Systemic Disease. Erling Falk, Denmark
Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem or Systemic Disease Erling Falk, Denmark Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationObserve the effects of atherosclerosis on the coronary artery lumen
Clumps and Bumps: A Look at Atherosclerosis Activity 4B Activity Description This activity features actual photomicrographs of coronary artery disease in young people aged 18 24 years. Students will observe
More informationArteriosclerosis. I/AAAAAAAACes/jTiOFGWrWZI/s1600/angina+aterosklerosis.jpg
Arteriosclerosis http://1.bp.blogspot.com/_smg3fxietuk/s96rjr9ewa I/AAAAAAAACes/jTiOFGWrWZI/s1600/angina+aterosklerosis.jpg Definition of Arteriosclerosis Arteriosclerosis is a general term for several
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More information